Osteoporosis Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: January 25, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 12.5 billion |
|
Revenue Forecast in 2030 |
US$ 17.18 billion |
|
CAGR |
3.6% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Treatment Type, Administration Route, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global osteoporosis treatment market was valued at US$ 12.50 billion in 2021 and is expected to register a revenue CAGR of 3.60% to reach US$ 17.18 billion by 2030.
Osteoporosis Treatment Market Fundamentals
Osteoporosis is a bone disease that occurs when the body suffers from high calcium deficiency for an extended period. Osteoporosis is a severe disorder wherein bones are weakened and become highly brittle; thus, they can be easily broken (fractured) by a fall or, in extreme instances, sneezing or a little bump.
There is no complete cure available for osteoporosis. However, effective treatment and therapy play a crucial role in maintaining and strengthening the bones of an individual suffering from this disorder. Osteoporosis therapy can reduce bone frangibility and stimulate bone growth by assisting the body in retaining a required amount of calcium. The treatment for osteoporosis involves medication, weight-bearing exercise, and a nutritious diet to help prevent bone loss or strengthen weak bones. Some complementary and alternative therapies are also used to control or heal osteoporosis without the need for the administration of drugs.
[4378034]
Osteoporosis Treatment Market Dynamics
The main aim of osteoporosis treatment is to decrease or prevent mineral loss. It enhances bone density, avoids bone fractures, and reduces disease-related discomfort. The osteoporosis treatment market is a large industry and is expected to demonstrate continuous revenue growth during the forecast period.
The revenue growth of the global osteoporosis treatment market is primarily attributed to the rising incidence of osteoporosis, primarily due to the increasing elderly population. According to WHO studies on osteoporosis, nearly 6.3% of men and 21.2% of women in the age group above 50 have osteoporosis. Almost 500 million individuals across the globe are likely to be affected by this disease.
The osteoporosis treatment market is also driven by an increased risk of bone fractures and the launch of novel pharmacological therapy solutions. Moreover, growing awareness among the population about the latest available therapies and drugs is also expected to boost the revenue growth of the market.
However, barriers such as medicine patent expiration owing to increased risk factors are likely to hinder the overall market expansion. Furthermore, adverse effects of osteoporotic medications, such as hot flushes, vomiting, leg cramps, bowel changes, and diarrhea, are also limiting the market revenue growth. Moreover, stringent regulations, delays in FDA approvals, and product recalls/suspensions are also expected to hamper the market expansion by limiting product sales.
Osteoporosis Treatment Market Ecosystem
The global osteoporosis treatment market is analyzed from four perspectives: treatment type, administration route, distribution channel, and region.
Osteoporosis Treatment Market by Treatment Type
[424231]
Based on the treatment type, the global osteoporosis treatment market is segmented into bisphosphonate, hormone replacement therapy, RANK ligand (RANKL) inhibitor, selective estrogen receptor modulator (SERMs), and others.
The bisphosphonate segment accounts for the largest revenue share of the global osteoporosis treatment market. This can be attributed to the comprehensive utilization of bisphosphonate as the first-line treatment for osteoporosis. The bisphosphonate segment is further sub-segmented into alendronate, risedronate, ibandronate, zoledronic acid, and others. It is most effective in significantly lowering fracture risk (by 25% to 70% on average), depending on the fracture site. Bisphosphonate drugs are chemicals from inorganic pyrophosphate that have a high affinity for bone hydroxyapatite, block farnesyl pyrophosphate synthetase, and cause cell death, inhibiting bone resorption. Alendronate (ALN), risedronate (RIS), and zoledronic acid (ZOL) are most commonly used and recommended owing to their proven effectiveness in increasing BMD (bone mass density) and lowering the risk of vertebral, non-vertebral, and hip fracture.
However, long-term usage of bisphosphonate is linked to decreased bone turnover and increased bone brittleness. Furthermore, for individuals who have been using it for a long period (typically more than 3 years, with a median treatment length of 7 years), excessive prevention of bone resorption might raise the risk of mandibular osteonecrosis or atypical femoral fracture.
Osteoporosis Treatment Market by Administration Route
Based on the administration route, the global osteoporosis treatment market is segmented into oral and parental.
The parental segment accounts for the largest revenue share of the global osteoporosis treatment market. The growth of this segment is majorly ascribed to the benefits of the parental route of administration compared to others. Parenteral administration allows for greater dosage and rate control, resulting in more predictable pharmacodynamic and pharmacokinetic characteristics. Furthermore, it provides the advantage of improved capacity to promptly administer a precise amount of medication since it is injected straight into the tissue and circulatory system, skipping liver processing. Thus, the oral segment is expected to demonstrate steady revenue growth during the forecast period owing to the product availability and preference of the physicians.
Osteoporosis Treatment Market by Distribution Channel
In terms of distribution channel, the global osteoporosis treatment market is segmented into online pharmacy, retail pharmacy, and hospital pharmacy.
The hospital pharmacy segment accounts for the highest revenue share of the market. This can be attributed to a large patient pool resulting in higher patient visits. Additionally, the availability of advanced technologies and presence of well-trained healthcare professionals in hospitals further drives the growth of this segment. Moreover, the key advantage of the hospital pharmacy segment is that it also distributes biological agents, parental drugs, and even chemotherapy medications, thus, accounting for a significant share of this market.
Osteoporosis Treatment Market by Region
Based on the region, the global osteoporosis treatment market is segmented into North America, Europe, Asia Pacific, and the rest of the world.
North America accounts for the largest revenue share of the global osteoporosis treatment market. This can be majorly attributed to the enormous base of the aged population, which is resulting in increase in the cases of osteoporosis in the region. According to the general studies by researchers and other organizations (such as WHO, American Society for Bone and Mineral Research (ASBMR), and International Osteoporosis Foundation), women majorly suffer from severe osteoporosis during postmenopausal due to low bone mass and prior vertebral fracture. Additionally, growing R&D activities to develop improved drugs and treatment therapies also contribute to the revenue growth of this regional market. Moreover, high awareness about early diagnosis with the available treatment for osteoporosis encourages the further development of this market. The presence of key players and increasing number of strategic collaborations and partnerships among them further drive revenue growth in the North America osteoporosis treatment market.
Osteoporosis Treatment Market Competitive Landscape
The prominent players operating in the global osteoporosis treatment market are:
Osteoporosis Treatment Market Recent Developments
The global osteoporosis treatment market was valued at US$ 12.5 billion in 2021.
The adverse effects of osteoporotic medications and stringent regulatory policies are restraining the revenue growth of the global osteoporosis treatment market.
The global osteoporosis treatment market is expected to register a revenue CAGR of 3.6% during the forecast period.
Amgen Inc., F. Hoffmann La Roche Ltd., Allergan Plc, Novartis AG, and Pfizer Inc are among the major players in the global osteoporosis treatment market.
The bisphosphonate (BP) segment dominates the global osteoporosis treatment market with the largest share.
*Insights on financial performance are subject to the availability of information in the public domain